Atovaquone Given With Radiation for Children With Cancerous Brain Tumors

Official title: Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on .

The short version

This study is testing whether a drug called atovaquone can be given safely along with radiation in children with brain tumors.

Read our full plain-language summary

What the trial team says

The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number
NCT06624371
Stage of testing
Phase 1
Conditions studied
High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant

Where it is running

This trial lists 2 sites.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.